RA Capital Management acquires USD 2.62 million of Artiva Biotherapeutics common shares
ARTV•Beneficial ownership increases
Following the transactions, beneficial ownership rose to 17,242,483 common shares held indirectly.
Open-market purchases reported
RA Capital Management, a director and 10% owner of Artiva Biotherapeutics, reported open-market purchases totaling 264,586 common shares.
Purchases were reported at weighted average prices of USD 9.55, USD 9.93, and USD 9.96.
